Affordable Access

Publisher Website

A new and efficient method to generate human IgG monoclonal antibodies reactive to cancer cells using SCID-hu mice

Authors
Journal
Immunology Letters
0165-2478
Publisher
Elsevier
Publication Date
Volume
47
Identifiers
DOI: 10.1016/0165-2478(95)00080-o
Keywords
  • Human Monoclonal Antibody
  • Scid Mouse
  • Lung Cancer

Abstract

Abstract Human monoclonal antibodies (mAbs) are very useful for treatment of cancer, but they are difficult to obtain since immunization of humans is not a practical proposition at present. As an approach to circumvent this problem, we have simultaneously inoculated cancer tissues and regional lymphnode cells obtained from lung cancer patients into SCID mice to allow in vivo stimulation of human lymphocytes against autologous cancer tissues. Human immunoglobulins, especially IgG, were observed in the SCID-hu sera, and some showed high reactivity to lung cancer cell lines. Testing of human B-lymphoblastoid cell lines obtained from SCID-hu spleen and thymus for antibody activity revealed 16–45% of them to be reactive to lung cancer cells. These percentages are high as compared with previous reports. Furthermore, we could establish 4 human IgG mAbs reactive to lung cancer cell lines. These results indicate successful stimulation of specific human lymphocytes in vivo, which thereby enables efficient generation of human monoclonal antibodies using SCID-hu mice.

There are no comments yet on this publication. Be the first to share your thoughts.